Prodotti competitors / Area Oncology
Eisai and Merck announce termination of P3 Study with pembrolizumab + lenvatinib in 1L r/m Head and Neck Squamous Cell Carcinoma (HNSCC)
![Immagine News](/media/l4el5htd/cat-2.jpg?anchor=center&mode=crop&width=722&height=442)
On August 25th, 2023, Eisai and Merck announced the termination of their P3 LEAP-010 trial (PCD: Nov 2023) of pembrolizumab (KEYTRUDA; PD-1 mAb) + lenvatinib (LENVIMA; VEGFR1/2/3 TKI) vs pembrolizumab in 1L PD-L1 selected r/m HNSCC as the combination did not demonstrate an improvement in the primary endpoint of OS
Key Highlights & Implications:
- The companies shared that two planned interim analyses were conducted by an independent data monitoring committee over an 11-month period, with the latest analysis unable to demonstrate an improvement in OS for the combination arm when compared against pembrolizumab monotherapy,and the likelihood of reaching the protocol-specified threshold for statistical significance for OS deemed to be too low
- The first analysis of the experimental arm showed a statistically significant improvement in PFS and ORR compared to the active comparator
- Merck and Eisai are performing a full evaluation of the data of the trial which they plan to share with the scientific community, however, no timelines were disclosed
- The termination of LEAP-010 ends the development of one of the most advanced competitor combinations in development for the PD-L1 selected 1L r/m HNSCC space; No new entrants are expected to read out pivotal data in the near future
- The P2 ASPEN-03 (PCD: Dec 2023) trial of evorpacept (SIRPa-Fc) + pembrolizumab is ongoing with the company previously communicating a readout by mid-2024
- While ALX has previously stated that they believe the surrogate endpoint of 12m-OS is registration enabling, approval based on P2 data is very unlikely, especially given the recent P3 failures in this space
- Immutep’s eftilagimod alpha (IMP321; LAG3 fusion protein) is also being assessed in combination with pembrolizumab in a P2 TACTI-003 (PCD: Dec 2023) with anticipated topline readout by year-end 2023
- The P2 ASPEN-03 (PCD: Dec 2023) trial of evorpacept (SIRPa-Fc) + pembrolizumab is ongoing with the company previously communicating a readout by mid-2024
- Despite the termination of LEAP-010, Eisai and Merck still have an active study currently recruiting in 2L r/m HNSCC P2 LEAP-009 (PCD: Aug 2024) assessing the same combination vs chemotherapy SOC
- The termination of this trial reiterates the bar set by the current SOC as well as the need for robust randomized P3 trials to demonstrate efficacy (OS) improvements in patients
Grazie per il tuo feedback!